Elsevier

The Lancet

Volume 361, Issue 9365, 12 April 2003, Pages 1267-1268
The Lancet

Research Letters
S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia

https://doi.org/10.1016/S0140-6736(03)12984-4Get rights and content

Summary

Pneumocystis carinii is unable to synthesise S-adenosylmethionine and thus scavenges this intermediate. We aimed to test whether measurement of concentrations of this metabolic intermediate in plasma could provide a new method for rapid diagnosis of Pneumocystis carinii pneumonia (PCP). We measured S-adenosylmethionine plasma concentrations in 12 healthy controls, 16 patients with confirmed or suspected PCP, and 36 patients with other infections. Median concentration in healthy controls was 106 nmol/L (range 86–128), but the protein was undetectable in eight patients with histologically proven and seven with suspected PCP, and was 8 nmol/L in another confirmed case (p<0·0001). In 36 patients with other infections, S-adenosylmethionine concentrations were much the same as in controls: 18 had bacterial pneumonia, two tuberculosis, five cryptococcal meningitis, three had other infections, and eight had asymptomatic HIV-1 infection. After treatment for PCP, S-adenosylmethionine concentrations rose rapidly in all but one patient who died of the disease. Measurement of plasma S-adenosylmethionine concentrations could prove useful for diagnosis of PCP and assessment of patients' response to treatment.

References (5)

  • S Merali et al.

    S-adenosylmethionine and Pneumocystis carinii

    J Biol Chem

    (2000)
  • JE Kaplan et al.

    Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy

    Clin Infect Dis

    (2000)
There are more references available in the full text version of this article.

Cited by (60)

  • Diagnosis of Pneumocystis pneumonia: Evaluation of four serologic biomarkers

    2015, Clinical Microbiology and Infection
    Citation Excerpt :

    These differences may be due to the use of distinct laboratory methodologies and sampling (high-performance liquid chromatography and plasma were used in previous studies instead of ELISA and serum) [29,30]. Additionally, this bias may be caused by differences in P. jirovecii burdens and by factors such as poor nutrition, medical conditions or other inherent variables (e.g. coexisting pulmonary malignancies), thus affecting the serum levels of this metabolite in a way that compromises its reliability as a diagnostic tool [24,29]. The high cost of the plasma SAM assay (US$300, €224.9 per sample specimen) is also an important limitation [29].

  • Nonmolecular methods for the diagnosis of respiratory fungal infections

    2014, Clinics in Laboratory Medicine
    Citation Excerpt :

    Detection of markers of the disease in serum thus represents an attractive alternative strategy. In 2003, measurement of plasma S-adenosylmethionine concentrations was proposed as a diagnostic tool of PJP.100 Because P jirovecii is not able to synthesize this essential metabolic intermediate, plasma S-adenosylmethionine from the host serves as an exogenous source for the pathogen and accordingly is depleted during PJP infection.

  • Accuracy of β-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: A meta-analysis

    2013, Clinical Microbiology and Infection
    Citation Excerpt :

    An incorrect clinical diagnosis of PCP could also be associated with failure to detect and treat other potentially serious conditions [3]. Some serum or plasma biomarkers have been studied with the aim of improving the diagnosis of PCP [9]. ( 1 → 3)-β-D-glucan (BDG) is a candidate such marker.

  • Pneumocystis pneumonia

    2012, Sande's HIV/AIDS Medicine: Medical Management of AIDS 2013
View all citing articles on Scopus
View full text